Case Managers and Peer Support Groups (CAMPS) for Prophylaxis Adherence in Rheumatic Heart Disease
Study Period: August 2022- July 2023
The CAMPS study is a pragmatic randomised field trial to test and evaluate scalable secondary antibiotic adherence support models for children newly diagnosed with rheumatic heart disease (RHD), integrated within routine care at the health centre IIIs and IVs over 12 months.
RHD is the most common acquired cardiovascular disease among children and young adults, with at least 40.5 million current clinical cases worldwide. RHD is responsible for 340,000 annual deaths and accounts for the most significant cardiovascular disease-related loss of disability-adjusted life years among 10-14-year-olds. Studies suggest that early diagnosis and initiation of secondary antibiotic prophylaxis (SAP) improves 2-year outcomes for children with latent RHD. However, long courses of SAP with every-4-week BPG are very challenging to maintain worldwide.
CAMPS aim to determine 1-year BPG adherence rates of children newly diagnosed with latent RHD in Uganda randomised to one of two support strategies: a) Usual care (Arm 1) and b) Peer group + Case Manager strategy (Arm 2). The primary outcome will be adherence to secondary antibiotic prophylaxis at 12 months. CAMPS will also explore patient-reported outcomes, including treatment satisfaction, patient health-related quality of life, and caregiver quality of life, in relation to support strategy.
The CAMPS study runs in the Tororo district in Eastern Uganda at 11 participating health centres.
Study Site: Tororo Hospital, Tororo District
Collaborators: Uganda Heart Institute (UHI)
Principal Investigators: PI- Joselyn Rwebembera, Co-PI Sarah deLoizaga Carney
Study Sponsor: Children’s Hospital Medical Center (“CHMC”)
